PMI 10-Q Details Q3 Revenue of $11.4B and Flags Abnormally Low Q4 U.S. Profit

summarizeSummary

PMI's Q3 10-Q confirms $11.4B revenue (+5.5%) and $2.12 diluted EPS (-4.9%), and warns Q4 U.S. profitability will be abnormally low as ZYN moves to 20-pouch cans, cutting revenue per pouch by about 25%.

check_boxKey Events · Earnings and Guidance · PM

• Q3 Revenue Up, EPS Down

  Net revenues rose 5.5% to $11,438 million from $10,845 million, but diluted EPS fell 4.9% to $2.12 from $2.23 on fair-value losses on equity investments and a higher tax rate.

• Q4 U.S. Profit Warning

  The ZYN flagship portfolio moves to 20-pouch cans from 15-pouch cans, which all else equal translates into approximately 25% less revenue-per-pouch, and PMI expects an abnormally low level of U.S. profitability in Q4 2026.

• Cash Flow Jumps

  Nine-month operating cash flow was $10,445 million versus $7,524 million, helped by $682 million of pension surplus refunds and lower working capital; full-year operating cash flow is guided to around $13.5 billion.

• Wellness Restructuring Risk

  In October 2026 PMI began restructuring Aspeya toward an asset-light model; the change may require revising wellness projections and could impair the $337 million of goodwill in that unit.

auto_awesomeAnalysis · PM · Manufacturing

The headline numbers were already out on October 21, but the full 10-Q carries the detail that matters: Q3 revenue rose 5.5% to $11.4B while diluted EPS fell 4.9% to $2.12, and management now explicitly warns that the fourth quarter will be a unique quarter of investment with abnormally low U.S. profitability. The cause is the shift of the ZYN flagship portfolio to 20-pouch cans, which all else equal cuts revenue per pouch by roughly 25%, plus extra retail changeover support and manufacturing capacity expansion. That is a real, dated hit to near-term U.S. earnings that investors should price in now, even though the top line and cash flow remain strong.